Paralos Bioscience Inc.

LOS ANGELES, CA · Founded 2024 · CIK 0002080259 · Biotech · Private

Phage-drug conjugates for targeted drug delivery

paralos.bio →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$50K
1 Form D · Aug 2025
14 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$50,000
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2668Orna Therapeutics——
2669ePurines, Inc.—$50K
2670AFFINITY MOLECULES LLC——
2671Paralos Bioscience Inc.—$50K
2672POTOMAC AFFINITY PROTEIN LLC——
2673Advanced Gene Transfer Company, Inc.——
2674ITERION THERAPEUTICS INC. ——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 2 related persons
  • Irene ChenDirector · Executive Officer
  • Yanxi YangExecutive Officer

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.